Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998052601) CLEAVAGE OF FIBRIN(OGEN) AND CROSS-LINKED FIBRIN BY FIBRINOLYTIC MATRIX METALLOPROTEINASES
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/052601 International Application No.: PCT/US1998/010364
Publication Date: 26.11.1998 International Filing Date: 20.05.1998
Chapter 2 Demand Filed: 03.12.1998
IPC:
A61K 38/48 (2006.01) ,C12Q 1/56 (2006.01) ,G01N 33/86 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43
Enzymes; Proenzymes; Derivatives thereof
46
Hydrolases (3)
48
acting on peptide bonds (3.4)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
56
involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
86
involving blood coagulating time
Applicants:
THE NEW YORK BLOOD CENTER, INC. [US/US]; 310 East 67th Street New York, NY 10021, US (AllExceptUS)
BINI, Alessandra [IT/US]; US (UsOnly)
Inventors:
BINI, Alessandra; US
Agent:
BARON, Ronald, J. ; Hoffmann & Baron, LLP 350 Jericho Turnpike Jericho, NY 11753, US
Priority Data:
08/859,73821.05.1997US
Title (EN) CLEAVAGE OF FIBRIN(OGEN) AND CROSS-LINKED FIBRIN BY FIBRINOLYTIC MATRIX METALLOPROTEINASES
(FR) RUPTURE DE FIBRINE/FIBRINOGENE ET FIBRINE RETICULEE PAR DES METALLOPROTEASES MATRICIELLES FIBRINOLYTIQUES
Abstract:
(EN) The invention provides a method of causing the degradation of fibrin(ogen) (i.e., fibrin, fibrinogen, and related substances) by means of a fibrinolytic matrix metalloproteinase, preferably an MMP-3 or MMP-7. The method of the invention can be performed $i(in vitro) to provide diagnostic information characterizing fibrin(ogen) and fibrinolytic physiology. The method can also be performed $i(in vivo) as a method of thrombolytic therapy in which a fibrinolytic matrix metalloproteinase is administered to a subject to degrade thrombus $i(in situ). The fibrinolytic matrix metalloproteinase can be administered in conjunction with other active agents, preferably with agents having thrombolytic activity to improve thrombolytic and fibrinolytic therapy. The invention further provides compositions containing a fibrinolytic matrix metalloproteinase for the performance of fibrinolytic or thrombolytic procedures. Also provided are kits that include a fibrinolytic matrix metalloproteinase for performing fibrinolytic or thrombolytic procedures.
(FR) Cette invention se rapporte à un procédé permettant de provoquer la dégradation de la fibrine/ du fibrinogène (et de substances associées) au moyen d'une métalloprotéase matricielle fibrinolytique, de préférence une MMP-3 ou une MMP-7. On peut mettre en oeuvre le procédé de cette invention $i(in vitro) de manière à recueillir des informations diagnostiques caractérisant la fibrine ou le fibrinogène et la physiologie fibrinolytique. On peut mettre en oeuvre ce procédé $i(in vivo) en tant que thérapie thrombolytique consistant à administrer une métalloprotéase matricielle fibrinolytique à un sujet en vue de la réduction d'un thrombus $i(in situ). On peut administrer la métalloprotéase matricielle fibrinolytique en association à d'autres agents actifs, de préférence des agents possédant une activité thrombolytique qui permettent de renforcer la thérapie thrombolytique et fibrinolytique. Cette invention se rapporte en outre à des compositions contenant une métalloprotéase matricielle fibrinolytique et destinées à l'exécution de procédures thrombolytiques ou fibrinolytiques. Enfin, l'invention a trait à des trousses comportant une métalloprotéase matricielle fibrinolytique destinée à l'exécution de procédures thrombolytiques ou fibrinolytiques.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU1998076904